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Objective: Treatment-resistance schizophrenia occurs in 20-30% of patients. Clozapine is the
only medication proven effective for treatment-resistant schizophrenia. However, less than 25%
of treatment-resistant schizophrenia patients receive clozapine in most settings. Therefore, this
study was conducted to identify facilitators and barriers to clozapine use, to inform development
of interventions to maximize appropriate clozapine-utilization.

Methods: Seventy semi-structured phone interviews were conducted with five high- and five
low-utilization VA Medical Centers, from different US regions including urban and rural areas.
Interviewees were key informants of clozapine processes, including mental health leadership,
psychiatrists, clinical pharmacists and advanced practice nurses. Interviews were analyzed
using an emergent thematic strategy to identify barriers and facilitators to clozapine prescribing.

Results: Key elements associated with high-utilization included integration of non-physician
psychiatric providers and clear organizational processes and infrastructure for treatment of
severe mental illness (e.g. clozapine clinics, larger mental health intensive case management
services). Low-utilization was associated with lack of champions to support clozapine processes
and limited-capacity care systems. Obstacles identified at both high- and low-utilization sites
included complex time-consuming paperwork, reliance on few individuals to facilitate processes,
and issues related to transportation for patients living far from care facilities.

Conclusions: Implementation efforts to organize, streamline and simplify clozapine processes,
development of a multidisciplinary clozapine clinic, increasing the size and capacity of existing
clinics, and provision of transportation are reasonable targets to increase clozapine utilization.
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Schizophrenia is one of the most disabling disorders. Although effective treatment is available,
20-30% of patients fail to respond to at least two antipsychotic medications, and are deemed to
have treatment-resistant schizophrenia.1 Clozapine has been proved superior to other
antipsychotics for treatment-resistant schizophrenia.2-4 Accordingly, evidence-based treatmentguidelines and Veterans Affairs (VA) policies agree that patients who do not respond to
adequate trials of two antipsychotics should be offered clozapine.5-10 However, clozapine is
associated with side effects including significant weight gain, diabetes and myocarditits.11,12
Clozapine is also subject to an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS)
program due to the risk of agranulocytosis. Monitoring requirements vary but many countries
have similar requirements making this study relevant across healthcare systems. The FDA
REMS program requires registration of the physician, patient and pharmacy, and frequent
monitoring and reporting of white blood cell and absolute neutrophil counts (ANC), although the
reporting of the ANC alone is now required.11,12 Thus, clozapine is both uniquely effective and
uniquely inconvenient, leading to an imperative to use it as much as possible, combined with a
“bother” factor that induces clinicians to avoid its use. Therefore, clozapine underutilization may
persist on the clinician side, in part, due to the increased prescribing complexity compared with
other antipsychotics. However, clozapine-utilization rates vary between facilities, suggesting it is
possible to achieve higher clozapine-utilization rates despite these challenges.13-14

Because clozapine is prescribed for a small minority of patients most treatment-resistant
schizophrenia patients receive less effective antipsychotics.13-16 Another concern is the
substitution of clozapine with supra-therapeutic antipsychotic doses and polypharmacy of nonclozapine antipsychotics, strategies generally found to be less effective than
clozapine.13,16,17,18,19 Thus, by under-using clozapine, the most vulnerable patients are being
prescribed less effective treatment. It therefore seems worthwhile to consider how clozapine use
might be increased, despite the known challenges.
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While there is no consensus on what proportion of patients should be treated with clozapine, all
treatment refractory patients should be offered clozapine unless there is an absolute
contraindication (e.g. history of myocarditis or clozapine-induced agranulocytosis).20 Since up to
30% of patients have treatment-resistant schizophrenia and recognizing that not all patients are
appropriate candidates or willing to take clozapine, one could estimate clozapine-utilization
should approach 20% of patients with schizophrenia. Indeed, one study reported 69% of
patients with treatment-resistant schizophrenia, roughly 20% of all patients with schizophrenia,
accepted clozapine treatment when offered. However, clozapine-utilization rates of less than 5%
are reported in multiple settings.13,14,18-20 While the challenges of the clozapine REMS and the
side effect profile undoubtedly contribute to low-utilization, nationwide VA data indicate some
sites approach 20% utilization, despite these challenges.15 Thus, low-utilization rates may not lie
solely in patient refusal or contraindications to clozapine.

Therefore, we conducted a qualitative study to identify facilitators and barriers to clozapine use
in the VA, at sites with the highest- and lowest clozapine-utilization. This focus on outlier sites
has the potential to help identify strategies that are both effective and at least moderately
feasible, since some sites have already succeeded in adopting them.21-13 This in turn can help
inform a feasible and effective strategy for implementing changes to improve clozapineutilization.

METHODS
Conceptual Model: The Consolidated Framework for Implementation Research (CFIR) and an
emergent thematic analysis strategy were used to inform our research and to develop interview
guides and for high- and low-utilization sites.24-29 CFIR is composed of five domains: intervention
characteristics, outer-setting, inner-setting, characteristics of individuals involved, and process
4

of implementation as well as 39 constructs and sub-constructs to identify and track barriers and
facilitators to change in complex medical systems.27,28 Framing the research with CFIR assisted
in designing and conducting a rigorous assessment of organizational characteristics of sites. 29

Study Sites: Using FY2013 VA prescribing data, facility-level clozapine-utilization rates were
calculated for patients with schizophrenia or schizoaffective disorder receiving clozapine at each
VA facility. The denominator was the total number of patients at the site with a diagnosis of
schizophrenia or schizoaffective disorder (ICD-9 code 295.x), and the numerator was the
proportion of these patients who received clozapine from a VA pharmacy during FY13. Using
this definition, clozapine-utilization across the entire VA system was 4%. Five high- and 5 lowutilization sites were requested to participate. Sites with non-zero rates of utilization were
contacted, as personnel at sites with zero-utilization might not be able to contribute useful
information. Sites were generally of different sizes, geographic regions, etc. This was easier to
accomplish with low-outliers due to the many sites fitting that description. Sites were not
informed of their utilization status.

Key Informants: Purposeful and chain-referral sampling approaches were used to identify
participants with expertise related to clozapine prescribing, policy and practice.30,31 The Chief of
Psychiatry was contacted at each site to identify potential participants. Potential participants
identified by the Chief were contacted to request their participation and to ask them to identify
potential participants involved in local clozapine policies, processes and prescribing (chainreferral sampling). Chain referral sampling was also used to confirm interview subjects were
considered experts on clozapine policy and practice by staff.32,33 Participants were divided into
leadership figures and front-line clinicians. Leadership figures may not directly prescribe or
manage clozapine, but are involved in creating, influencing or implementing policies or
managing departments integral to clozapine processes (i.e. laboratory, information technology,
5

psychiatry and pharmacy). Front-line clinicians were directly responsible for prescribing or
managing patients receiving clozapine (i.e. psychiatrists, advanced practice nurses, clinical
pharmacists).

Interviews: Semi-structured telephone interviews were conducted between September 2014
and May 2015. Participants provided informed consent prior to the interview. Interview guides
were informed by CFIR and relevant literature.27,28 Interviews focused on perceptions of
clozapine risks and benefits, local and national clozapine policies and processes (formal and
informal), departmental interfaces regarding clozapine-utilization, sources of clozapine policies
and procedures, and patient perceptions of clozapine.

Data Analysis: Coding and analysis of interview transcripts was completed by experts in
qualitative research methods (RE and MM) and experts in medicine and psychiatry with
qualitative research experience (JG and AR). All coders conducted interviews. The codebook
was developed using inductively-informed grounded thematic analysis.24-26 The finalized
codebook identified broad themes relating to “domains” regarding clozapine beliefs, policies,
practices and processes. Once the codebook was finalized, interrater consensus was reached
through an iterative process with four interviews coded by all four team members. The
remaining interviews were coded by one investigator except for two interviews coded by all four
to ensure continued inter-rater reliability. Each investigator coded interviews from different sites
and job roles. Next each facility was assigned to one investigator, who independently reviewed
all coded interviews for that site and synthesized data into a profile of that site’s organizational
structure, clozapine management policies and procedures, and beliefs related to clozapine.
Thus interviewee data was triangulated so provider perceptions of individual and organizational
structures and processes of care could be analyzed and contextualized within site and across
sites. Quote tables containing representative quotes from sites were developed for each
6

domain. Finally, looking across site profiles, the team identified thematic domains that defined
the differences between high- and low-utilization sites. All data were coded and analyzed using
NVivo 10.
This study was approved by Edith Nourse Rogers Memorial Veterans Hospital, Bedford,
Massachusetts Institutional Review Board.

RESULTS
Seventy interviews were conducted five sites in the top 10% for clozapine-utilization (> 8% of all
patients with schizophrenia) and five sites with lower than median utilization (< 4%) (Tables
1&2).

Five thematic domains related to clozapine-utilization were identified. (Table 3) Domains were
conceptualized based on potential to develop interventions unique to each domain. Each
domain is discussed in detail below, with Table 4 providing representative quotes from each
domain.

Transportation: The most pervasive issue was patients’ needs and resources related to
transportation for weekly visits and laboratory monitoring. Lack of reliable transportation was
mentioned by low- and high-utilization sites, even at sites located in environments with adequate
public transportation. Reasons cited included disorganized patients’ inability to navigate public
transit, patients too paranoid to ride public transit, and cost of transportation. Patients living far
from care facilities were not considered clozapine candidates, regardless of clinical need, because
of perceptions patients could not attend weekly visits. Sites with higher clozapine-utilization often
had greater availability of transportation services (e.g. van to bring patients to appointments).
Transportation services were often located within mental health intensive case management
7

(MHICM) services; while all sites had MHICM, more clozapine patients were enrolled in MHICM at
high-utilization sites. However, even high-utilization sites struggled to provide clozapine for
patients living far from care.

Capacity: Clozapine prescription requires multiple administrative processes including
registration of physician, patient, and pharmacy, review of informed consent, and weekly visits.
Thus, there must be adequate clinician availability to accommodate increased visit frequency
and complete required paperwork, processes, monitoring and reporting. Low-utilization sites
cited increased prescriber burden as a primary barrier to clozapine-utilization.

Both high- and low-utilization sites expressed concerns over capacity to accommodate
increased prescribing burden associated with clozapine. Even among high-utilization sites, only
three achieved clozapine prescribing rates above 10%. Low-utilization sites reported limited
capacity prevented meaningful clozapine use. High-utilization sites often reported the clozapine
clinic was functioning at or above capacity.

Multi-disciplinary teams: From analysis of capacity it was clear that a related but independent
thematic domain was the issue of multi-disciplinary teams. In this theme data were captured and
analyzed on the use of non-physician providers as well as the gaps and strains at sites that relied
solely on physicians.

High-utilization sites addressed capacity issues in part through integration of non-physician staff
into the clozapine team. Advanced practice nurses and clinical pharmacists completed clozapine
related tasks (e.g. registration, ordering and monitoring laboratories, evaluating side). Lowutilization sites relied on physicians to complete these tasks. Low-utilization sites expressed the
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need for more clinical pharmacists in mental health care in general, but especially to facilitate
the clozapine use.

Care Coordination: While all providers are required to follow the REMS monitoring parameters,
the process of care was significantly different at high- and low-utilization sites. For example,
high-utilization sites often had a clearly defined point person or clinic system to organize clozapine
care. Multiple entities, including the clozapine registry, psychiatry, laboratory, and pharmacy, all
play a role in clozapine prescription, necessitating considerable coordination among departments
and often with the patient or patient’s family. In addition, these steps must happen in a specific
sequence within narrow timelines. High-utilization sites addressed these issues through
development of clozapine clinics to coordinate care. Clozapine clinics were largely defined by the
presence of multi-disciplinary teams, adequate time to accommodate increased visit frequency
and dedicated support staff. Clozapine clinics were seen as integral to providing clozapine care,
with high-utilization sites unable to imagine providing clozapine without a clozapine clinic.

While having a clozapine clinic was beneficial, it still limited patient access. Once the capacity of a
clinic was reached, a decision would need to be made to expand the clinic, often by adding an
additional session requiring allocation of resources or having additional patients treated outside
the clinic, meaning a much greater burden for physicians.

Maintaining adequate psychiatric staff is an ongoing issue for many facilities, but particularly for
low-utilization sites. Frequent staff turnover was reported by some as a barrier to the continuity of
care necessary to ensure coordination of clozapine treatment.

Another barrier was the accumulation of many small process delays, which added up to bigger
delays for patients. At some facilities a weekly clozapine visit was an all day affair, due to delays
9

before blood draws, processing laboratory results, clinic visits and dispensing the prescription or
limited access to transportation. Lack of coordination made it difficult to accommodate patients
who lived far away and had difficulty getting to the medical facility on clozapine clinic days. Highutilization sites were more flexible in terms of scheduling outside of clinic hours, offering walk in
hours or same day appointments.

Overreliance on a Few: This domain pinpoints a systems and processes issue noted at highand low-utilization sites. While having committed clozapine champions was essential, it was not
sufficient to ensure access to clozapine. Many sites relied on 1-2 clozapine champions. However,
overreliance on too few people left sites vulnerable when staff were away due to illness, annual
leave, or retirement. Even high-utilization sites were vulnerable in this way, though they usually
relied on 3-4 people, rather than one or two as was the case at low-utilization sites.

DISCUSSION
We interviewed key informants at high- and low-clozapine-utilization facilities, to understand
what specific factors prevented or facilitated clozapine-utilization. Via triangulation of key
informant data within and across sites, we identified barriers that actually exist versus barriers
that are only perceived Through this analysis we found that high-utilization sites had
commonalities, among them providing access to transportation, having sufficient capacity to
enroll patients, utilization of multidisciplinary teams including non-physician providers, better
coordination of care, and creation of systems to reduce reliance on too few individuals.

These findings suggest that clozapine clinics staffed by a multidisciplinary team, with adequate
time to accommodate increased visit frequency and prescribing burden of clozapine, could
improve access to evidence-based care for patients with treatment-resistant schizophrenia. This
would include development of clozapine clinics at sites without one, and expansion of clozapine
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clinics where one already exists. Clearly defined clinical structure and staff roles may improve
the effectiveness of clinics.34 In addition, this study suggests that the straight forward act of
providing transportation for patients to and from clozapine appointments has the potential to
greatly expand the pool of patients who would be able to receive this potentially life-changing
medication. Home visits have been a successful tool for some clozapine programs and could
also address this issue.20

There have been other similar studies using qualitative interviews of outlier sites to gain insight
into how to organize care to achieve the best results.22,23 Some of our findings echo earlier
studies. In particular, previous studies reported the importance of adequate staffing and
effective integration of non-physicians into patient care are key ingredients in the success of
programs as diverse as anticoagulation clinics and hospital teams caring for patients with acute
coronary syndromes.22,23 In a study of clozapine patients, multi-disciplinary teams were
associated with improved medical monitoring.35 Thus, a more effective use of multidisciplinary
teams could improve access and outcomes across a multitude of settings.

One of the strengths of this study is the focus on strategies that work well within the current
system and rules, rather than ideas that rely on changing those rules, which may not be
possible.20 While all of the changes or initiatives suggested by this study may be feasible (i.e.
allowed under the rules), some of these changes would require commitment of resources.
However, data suggest cost-savings with incremental increases in clozapine-utilization. Thus
increased outpatient costs may be outweighed by cost-savings from reduced inpatient
hospitalizations.36,37 In a companion study published in this issue of Psychiatric Services, we
demonstrated incremental increases in clozapine-utilization could result in substantial costsavings, primarily through decreased use of inpatient admissions. Thus, implementation of
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interventions derived from this study could more than pay for themselves, if they succeed in
increasing clozapine-utilization for treatment-resistant schizophrenia.

Patients who live far from clinics are a unique and difficult group to reach, and are not well
served even by the highest-utilization sites studied. This means that a fairly large subset of
patients essentially has no access to clozapine. Some of the solutions discussed above would
help to reach this population as well. The most feasible solution would involve providing
transportation or home-based care to patients who live far from clinics, which would admittedly
be more expensive and laborious than providing these services to patients living closer. Some
other solutions, like increased use of outside laboratories or point-of-care testing for blood count
monitoring, would be difficult to implement within VA, because they may require national policy
change. However, point-of-care testing should be considered as clozapine patients report it to
be more convenient and less painful than traditional venipuncture.38

This study does have some limitations. First, the VA limits clozapine prescribing to psychiatrists
and neurologists. Thus some obstacles encountered in the VA may not be an issue for other
care settings. Second, telephone interviews may be suboptimal in some cases, in part because
of missing non-verbal cues and difficulty developing rapport. However, many of the interviews
were much longer than anticipated, suggesting that participants felt comfortable sharing their
experiences. Additionally, surveys of clinicians have reported similar findings.39 Thirdly, what we
deemed high-utilization may not reflect optimal-utilization as this optimal rate has not been
defined. Lastly, VA sites may not be representative of other healthcare systems. However, the
side effects, FDA REMS requirements and low-utilization for clozapine are the same inside and
outside VA, suggesting the challenges that need to be overcome in other systems are similar to
those faced by the sites we studied. This is true even in light of the changes to the clozapine
REMS program, which still requires registration of physician, patient and pharmacies, frequent
12

monitoring, and limitations on days supplied. These interventions may prove useful in other
countries with similar monitoring requirements.

In a separate study we found some relatively straightforward changes are associated with
higher clozapine-utilization within the VA. Among these are having a dedicated clozapine clinic,
ensuring the clinic has sufficient capacity to accommodate all patients with TRS and adequate
levels of staffing in the clinic by non-physicians including RNs and pharmacists and providing
transportation for appointments for clozapine patient. While all of these strategies are allowable
under VA rules and regulations, and are currently done at some sites, they are not without cost.
It is hoped that the present study can provide an impetus to make these relatively
straightforward, if not inexpensive changes. Extrapolating from our findings here, an average
sized VA site (managing 700 patients with schizophrenia) could expect to have a population of
140 patients with TRS. Increasing the proportion of patients treated with clozapine from 20% to
40% would save the facility greater than $625,000 in the first year. It is difficult to imagine the
cost of implementing our recommendations could approach this figure. Thus, even a modest
increase in clozapine-utilization, achieved at a very high cost, and could still result in a net cost
savings for VA.

CONCLUSIONS
Using qualitative research methods, we examined differences between VA sites that use
clozapine at the highest and lowest rates. We found that a number of strategies already pursued
by high-outlier sites would be feasible to implement in a broad variety of settings. These
strategies included starting a clozapine clinic where none exists, ensuring that clozapine clinics
have sufficient capacity to handle the number of patients for whom clozapine is indicated,
providing transportation to all patients receiving clozapine and ensuring adequate staffing, and
integration of non-physician clinicians within clozapine clinics. While other strategies could also
13

be considered, in many cases they would require national-level policy changes that could prove
challenging to pursue. Used in combination, and pursued diligently, the more feasible strategies
identified in this study would likely be sufficient to reach the goal of providing clozapine to all
appropriate patients.
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Table 1: Key informants by position and number of interviews
Interviews

N

Mental health leadership

11

Pharmacy leadership

5

Psychiatrist

22

Clinical pharmacist specialist

12

Advanced practice nurse

4

Dispensing pharmacist

9

Laboratory staff

3

Other*

4

Total interviews

70

*RN, clinic coordinator, medical technologist, social worker
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Table 2: Site Characteristics
Facility

High

Clozapine

Patients with

/Low

Utilization

Schizophrenia

Region

Number of

Clozapine

Multi-

Significant

Interviews

Clinic

disciplinary

Transport

Rate*

Support

A

High

10%

590

Midwest

8

Yes

Yes

Yes

B

High

8%

1080

Northeast

7

Yes

Yes

Yes

C

High

15%

290

Midwest

12

Yes

Yes

No

D

High

10%

450

West

7

Yes

Yes

Yes

E

High

9%

660

Southeast

4

Yes

Yes

No

F

Low

2%

550

Northeast

6

Yes

Yes

No

G

Low

4%

1170

West

9

Limited#

Yes

No

H

Low

1%

450

Southeast

8

No

No

Yes

I

Low

2%

1510

Southeast

6

No

No

No

J

Low

3%

1830

Midwest

3

No

No

No

*Percentage of patients with schizophrenia receiving clozapine in 2013

#

Clozapine clinic was available but given limited capacity and rigidity regarding seeing patients outside of set clozapine clinic hours

many clozapine patients were still treated by individual clinicians outside the clinic
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Table 3: Thematic Domains and Definitions
Thematic Domain

Definition

Transportation

A multifaceted issue related to the need for transportation to frequent
medical visits. The domain was directly related to the distance to and from
medical centers as well as the distance between community based
outpatient clinics and major medical centers.

Capacity

Multiple reasons account for sites’ ability, or lack thereof, to prescribe
clozapine. The domain was directly related to staffing and scheduling
issues.

Multidisciplinary

Availability and incorporation of non-physician staff impacted sites’ ability

care teams

to initiate patients on clozapine treatment as well as to prescribe clozapine
for patients maintained on clozapine.

Care coordination

Oversight of clozapine prescribing process was a key component in sites’
ability to use clozapine. The domain was related to champions, clear
processes and ready identification of people “in charge” of clozapine.

Over-reliance on a

Utilization of only a few people to facilitate clozapine processes left

few

systems vulnerable when key personnel were away or unavailable.
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Table 4: Representative Quotes From Each Domain
High Utilization Site

Low Utilization Site
Transportation

Site D: Clinical Pharmacist

Site I: Psychiatrist

[Intensive case management staff] are

[It’s true that] not that many people like getting

either able to go and get them and bring

blood draws…. [But] the frequent appointments,

them into clinic, or if there are residing out

the distance, a lot of people come from an hour

in an assisted living facility, we can

away and just the logistics of coming in for

coordinate with the facility to bring them in.

frequent monitoring sometimes is an issue. The

All our [intensive case management]

side-effects doesn't usually seem to be the factor.

veterans do have a lot more supports in
place to help them get into Clozaril Clinic
without difficulty.
Capacity
Site B: Pharmacist

Site I: Mental Health Leadership

We had to tell inpatient team to stop

People [staff] have full schedules; we are a huge

referring to clozapine… because we were at

facility and for a certain time over the past two

capacity. So there were these two solutions

years we grew up faster than we were able to

– give us [staffing for] another day or we’ll

record people and so there was time when

have to start discharging patients.

people [didn’t] have a next available appointment
for another three or four months and I think
availability and accessibility is definitely a factor
and this is why [we are developing a] Clozaril
Clinic, trying to diffuse… that … barrier.
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Site C: Psychiatrist

Site H: Nurse Practitioner Intensive Case

I have a Clozapine Clinic, on Tuesday

Management

morning and then, I have…quite a bit of

I think it's a very effective medication. In fact, I

overflow on Mondays and I do it as a walk-

say when nothing else works, clozapine definitely

in clinic.

will work, and it does keep 'em out of the
hospital. I don't know that we have the staff that
can monitor the face-to-face follow-up that is
really needed.
Multi-Disciplinary Teams

Site D: Clinical Pharmacist

Site G: Psychiatrist

We have a number of different people in

Once we had a clinical pharmacist on board it,

the clinic…we have one psychiatrist, Dr. X

made managing patients on clozapine…and

who is Head Psychiatrist over at the clinic.

getting new starts much, much easier… I basically

It's managed by a nurse, who keeps tabs

would recommend that every mental health,

on the patients who are supposed to be

outpatient clinic, have a [mental health]

coming in for that day and prints us out a

pharmacist assigned to them to help manage

list of who those patients are. I serve as a

[clozapine] patients.

provider in the clinic and we have another
psychiatrist who serves as a provider and
then when we have residents, we have
them serve as providers for clinic. We
meet together in the morning and we're
given the list of patients that we'll be
seeing for that day and then it's kind of an
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open clinic so the patients show up at their
leisure. …if I were to see a patient
because I cannot write Clozaril orders, I
would see the patient, do my evaluation
and assessment and then I would [discuss
the patient] with our chief psychiatrist and
make my recommendations and then…[Dr.
X] decides whether to take our
recommendations or not and then puts in
the orders for the patients.

Care Coordination
Site C: Clinical Pharmacist

Site F: Social Worker

I think that it would be helpful to have a

I don't know that I could treat more patients…who

specific Clozapine clinic with providers who

are on Clozapine because it's so labor-intensive…

are more familiar with [clozapine]…[and

I have to worry where they are and track them

people] who have the time to sit down with

down and make sure they come in. Has a blood

the patient and arrange for all of their lab

test been ordered? Are their appointments in the

appointments and their med renewals and

computer? Is there somebody here to draw their

everything…have somebody who focuses

blood? I mean, there [are] so many details that

on that because it is time-consuming.

have to be seen to…it just doesn't all happen by

There's a lot of paperwork and stuff that

itself.

goes along with it.
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Site A: Pharmacist

Site G: Psychiatrist

It worries me when … there's not somebody

Monitoring patients new to clozapine is kind of

coordinating it…if we didn't have our clinic

hard to do, especially when you're busy with a

downstairs I don't know how any of these

whole bunch of other patients. Checking to make

guys could stay on track. I really don't know

[sure] their labs are okay and then writing the

how that would work. So if there are VAs

prescription every single week, I don't feel like I

that don't [have a clozapine clinic], I can't

could have many patients on that kind of regime.

imagine how they're doing [prescribing
clozapine]. But maybe it's a requirement.
Like I said… I'm not sure.
Over-Reliance on a Few
Site E: Pharmacist

Site G: Clinical Pharmacist

[The clinical pharmacist] is trying to do

[The other staff] just wait until I get back [from

everything good and smooth. ..she does a

vacation]…There’ve been a couple of times when

phenomenal job. She goes out of her way,

it’s been delayed…several days, even up to a

she is always accessible. She leaves her

week.

phone number, even [when] she was out of
country… so I can’t really tell you…how
smooth it [would go] without her.

Site A: Psychiatrist
He does [play an integral part]. If he's not
there and the nurse…[isn’t] there I can
sometimes get in his drawer and figure out
where things are or go through the process
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that we use [to prescribe clozapine].
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